The clinical trial sponsored by Antalya Training and Research Hospital aims to evaluate the efficacy of the DASH diet in managing MASLD in children aged 11-18 years. Given the rising prevalence of MASLD alongside childhood obesity, this study addresses a significant unmet medical need. The market for pediatric liver disease management is expanding, particularly as awareness of non-alcoholic fatty liver disease grows. The trial's focus on dietary interventions may position it favorably against pharmacological approaches, which are currently limited. Successful outcomes could lead to the establishment of dietary guidelines and interventions that could be monetized through partnerships with healthcare providers and nutrition-focused organizations.